The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine the efficacy of naltrexone in the treatment of cocaine dependence as measured by: 1) decreased urine benzoylecgonine (BE) levels, 2) decreased cocaine use by self-report, 3) decreased cocaine craving, and 4) retention in treatment.
Condition or disease
Double-blind, placebo controlled study of the safety and efficacy of naltrexone in treating cocaine dependence in a patient sample that initiated the study while in an inpatient setting and were then followed-up for 3 months as outpatients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Meet DSM-III-R criteria for cocaine dependency,
18 to 65 years of age,
capable of understanding the study,
voluntarily signed consent,
male or non-pregnant female using approved form of birth control.
abnormal liver function tests (SGOT, SGPT, or GGT greater than twice the normal values),
opioid use within the last 7 days,
use of neuroleptics,
having a severe acute medical problem,
unable to complete psychiatric rating scales, or
judged by the investigator to be unlikely to comply with the study protocol